Search Within

Sloan Kettering Institute Postdocs

Formats
  1. Journal Article (8045)
  2. Meeting Abstract (3693)
  3. Review (630)
  4. Editorial (263)
  5. Book Section (195)
  6. Conference Paper (161)
  7. Research Letter (139)
  8. Correspondence (68)
  9. Miscellaneous (67)
  10. Guidelines (30)
  11. Book Whole (6)
Groups
  1. GSK Faculty (6365)
  2. Department of Medicine (4813)
  3. Sloan Kettering Institute Faculty (3571)
  4. Center for Molecular Imaging and Biotechnology (CMIB) (3037)
  5. Surgery (2635)
  6. Solid Tumor Oncology Division (2607)

More Groups

People
  1. Britta Weigelt (376)
  2. Jorge Reis-Filho (328)
  3. Mithat Gonen (319)
  4. Marc Ladanyi (309)
  5. Michael Berger (288)
  6. Joseph Deasy (285)

More People

Years
  1. 2026 (1)
  2. 2025 (706)
  3. 2024 (1081)
  4. 2023 (1152)
  5. 2022 (1366)
  6. 2021 (1179)

More Years

Publications
  1. Blood (680)
  2. Cancer Research (543)
  3. Journal of Clinical Oncology (431)
  4. Journal of Nuclear Medicine (271)
  5. Annals of Surgical Oncology (264)
  6. Clinical Cancer Research (249)

More Publications

Publishers
  1. Nature Publishing Group (1350)
  2. Elsevier Inc. (1106)
  3. American Association for Cancer Research (1058)
  4. Springer (842)
  5. American Society of Hematology (740)
  6. Cell Press (740)

More Publishers

Results (13297)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Mcm2 deficiency leads to bone marrow failure and lymphoid malignancies dependent on age and genetic background
    Meeting Abstract

    Matsukawa, T.; Yin, M.; Baslan, T.; Chung, Y. J.; Cao, D.; Bertoli, R.; Zhu, J.; Walker, R. L.; Freeland, A.; Knudsen, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Defining new reference intervals for serum free light chains in individuals with reduced kidney function: Results of the population- based on Iceland screens treats or prevents multiple myeloma (iStopMM) study
    Meeting Abstract

    Long, T. E.; Indridason, O. S.; Palsson, R.; Rögnvaldsson, S.; Love, T. J.; Thorsteinsdottir, S.; Sverrisdottir, I. S.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The BMP/SMAD pathway is a key mediator of leukemic transformation of TP53-mutant post-MPN AML
    Meeting Abstract

    Li, B.; An, W.; Wang, H.; Krishnan, A.; Mowla, S.; Baslan, T.; Koche, R.; Xiao, W.; Lowe, S.; Levine, R. L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Rhesus macaques as a preclinical model organism for RUNX1-FPD
    Meeting Abstract

    Lee, B. C.; Zhou, Y.; Bresciani, E.; Ozkaya, N.; Shin, T.; Hong, S. G.; Liu, P. P.; Dunbar, C. E.
    Blood (2021)

    Fulltext@MSK | Save
  • High-dose methotrexate is not associated with reduction in CNS relapse in patients with aggressive B-cell lymphoma: An international retrospective study of 2300 high-risk patients
    Meeting Abstract

    Lewis, K. L.; Jakobsen, L. H.; Villa, D.; Bobillo, S.; Smedby, K. E.; Savage, K. J.; Eyre, T. A.; Cwynarski, K.; Caporn, P. L.; Van Zyl, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Screening for monoclonal gammopathy of undetermined significance: A population-based randomized clinical trial. First results from the Iceland screens, treats, or prevents multiple myeloma (iStopMM) study
    Meeting Abstract

    Kristinsson, S. Y.; Rögnvaldsson, S.; Thorsteinsdottir, S.; Reed, E. R.; Oskarsson, J. T. T.; Petursdottir, I.; Sigurdardottir, G. A.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R. C.; Brunner, J.; Byrne, J.; Eliason, L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world experience
    Meeting Abstract

    Hultcrantz, M.; Orozco, J.; Peterson, T. J.; Derkach, A.; Hassoun, H.; Korde, N.; Lu, S. X.; Mailankody, S.; Patel, D.; Shah, U. A.; more...
    Blood (2021)

    Fulltext@MSK | Save